Dr. Dong has two decades of experience in drug discovery and development, and has contributed in various roles to 16 IND filings. Two of these investigational drugs are currently in Phase III clinical trials. From 2010 – 2015, Qing served as CSO of Shanghai Hengrui Pharmaceutical, Co., Ltd. where he led a team of 200 researchers that conducted research in multiple therapeutic areas (oncology, inflammation, cardiovascular diseases and diabetes). From 2003 – 2009, Qing served in various roles at Syrrx/Takeda San Diego including Director of Chemistry. Dr. Dong obtained his Ph.D. degree in Organic Chemistry from Rice University and conducted postdoctoral research at Harvard Medical School.
Stan Jin, Ph.D., VP of Chemistry
Dr. Jin has contributed to the discovery of a number of clinical development molecules during his 13 years in the biotech industry. Most recently, Dr. Jin founded and served as CEO and CSO of C2 Pharmaceuticals from 2012 to 2015, where he conceived and created a portfolio of oncology/immunology assets.  Prior to becoming an entrepreneur, Stan was a global project leader at Takeda from 2007 to 2012, where he collaborated with Dr. Dong and others to produce various development candidates using Structure-Based Drug Discovery methods.  He started his industrial career as a medicinal chemist in the areas of antibiotics and oncology at ICOS from 2004 to 2007.  A chemist by training, Stan received a Ph.D. from Texas A&M University and did postdoctoral research at University of Notre Dame.
Gene Hung, M.D., SVP of Biology and Drug Discovery
Dr. Hung has extensive experience in both clinical and basic research in Clinical Translation Research as well as Drug Development in multiple human disease areas. Prior to joining FronThera, Gene was at Ionis Pharmaceuticals, most recently as executive director of Experimental and Molecular Pathology, where he co-led the collaboration between Ionis and Dr. Krainer at Cold Spring Harbor labs which ultimately led to the FDA approval of Spinraza for the treatment of spinal muscular atrophy (SMA), an orphan disease in pediatric and adult patients. Previously, Gene was Director of Molecular Pathology at Arena Pharmaceuticals, and Chief and Principal Scientist at House Ear Institute Affiliated Institute of USC where he also held adjunct professor position. Dr. Hung received his M.D. at Tianjin Medical College, Tianjin, China and did postdoctoral training at the USC Keck School of Medicine.
Steve Kaldor, Ph.D., Strategic Advisor
Dr. Kaldor is a seasoned biotech and pharmaceutical industry executive with over 25 years of experience in creating high value drugs and shareholder value. Most recently, he served as CEO of Quanticel, a privately-held cancer drug discovery biotech that was acquired by Celgene in 2015 for $485M. Steve has contributed to other companies including Syrrx (President & CSO, 2005 $270M acquisition by Takeda), Amira (Independent Board Member, 2011 $475M acquisition by BMS), Ambrx (CEO & President), and Furiex (NASDAQ: FURX, Independent Board Member, 2014 $1.46B acquisition by Forest/Actavis), and is a co-inventor of several marketed drugs (Viracept®; Nesina®). Steve started his career at Lilly and is a chemist by training (Columbia B.A.; Harvard Ph.D.).
Gail McIntyre PhD, DABT
Dr. McIntyre has over 25 years of experience in drug discovery and development. She led PPD’s Compound Partnering Group for 7 years and was SVP at Furiex, responsible for identifying, assessing and managing full development programs. Her expertise is in toxicology and translating preclinical data into the clinic.
Laura Bonifacio PharmD, PhD
Dr. Bonifacio brings expertise in designing and driving early development programs that align corporate strategy and scientific goals. She manages multi-disciplinary operations teams for IND-enabling and clinical programs. She has experience in supporting successful investigational new drug and marketing applications.
Sailash Patel MBA
Sailash is a seasoned leader in start-up and multinational companies with extensive experience in financial and organization planning, corporate strategy development, mergers and acquisitions, licensing, market research and business integration. He has supported transactions with an aggregate value of $2 billion.
Sandart LLC:
Jayachandra P. Reddy, Ph.D.
Jay received his PhD in Organic Chemistry from the University of Kansas and was a staff researcher/lecturer under a post-doctoral fellowship at Indiana University. Over 20+ years in the pharmaceutical industry, he has led CMC teams at innovator firms such as Bristol-Myers Squibb, Neurocrine Biosciences and Takeda, as well as P&L business units at CDMOs such as AMRI and Johnson Matthey. Jay has been involved in numerous CMC programs during his career and has played pivotal roles in several from Advanced Lead to Commercial stages. He also co-founded AAO, a privately-held CDMO that was successfully acquired and integrated into AMRI. Most recently, Jay had P&L responsibility for the Pharmaceutical Materials and Services businesses at Johnson Matthey with sites in North America and China. Jay currently heads Sandart LLC, a boutique firm that provides strategic advisory services, supporting select clients in the pharmaceutical industry. He joined the FronThera Pharmaceuticals team in late 2016.
INVESTORS Haisco agreed to commit $30M to FronThera to enable creation of the FronThera R&D pipeline.
For more details on Haisco, see: